Partial splenic embolization prior to combination therapy of interferon and ribavirin in chronic hepatitis C patients with thrombocytopenia

Hepatology Research

Volumn 38, Issue 10, 2008, Pages 980-986

  Miyake, Yasuhiro ^a   Ando, Masaharu ^a   Kaji, Eisuke ^a   Toyokawa, Tatsuya ^a   Nakatsu, Morihito ^a   Hirohata, Mamoru ^a  

^a Mitoyo General Hospital   (Japan)

Author keywords

Chronic hepatitis C; Interferon; Partial splenic embolization; Ribavirin; Thrombocytopenia

Indexed keywords

HEPATITIS C ANTIBODY; INTERFERON; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ANEMIA; ARTICLE; ARTIFICIAL EMBOLISM; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATIC COMA; HEPATITIS C; HUMAN; HYPERSPLENISM; HYPOTHYROIDISM; LEUKOCYTE COUNT; MALE; NEUTROPENIA; NEUTROPHIL COUNT; PARTIAL SPLENIC EMBOLIZATION; PLEURA EFFUSION; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

EID: 51349151603     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2008.00357.x     Document Type: Article

References (25)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 9: 558-67.
2. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 2095-100.
3. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
4. Yoshida H, Shiratori Y, Moriyama M et al. Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131: 174-81.
5. Shiratori Y, Ito Y, Yokosuka O et al., Tokyo-Chiba Hepatitis Research Group. Antiviral therapy for cirrhotic hepatitis C: Association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142: 105-14.
6. Everson GT, Hoefs JC, Seeff LB et al., HALT-C Trial Group. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C. Lessons from the HALT-C trial. Hepatology 2006; 44: 1675-84.
7. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007; 46: 37-47.
8. Helbling B, Jochum W, Stamenic I et al., Swiss Association for the Study of the Liver (SASL). HCV-related advanced fibrosis/cirrhosis: Randomized controlled trial of pegylated interferon alpha-2a and ribavirin. J Viral Hepat 2006; 13: 762-9.
9. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis 2002; 22: 83-96.
10. Hayashi H, Beppu T, Masuda T et al. Predictive factors for platelet increase after partial splenic embolization in liver cirrhosis patients. J Gastroenterol Hepatol 2007; 22: 1638-42.
11. Foruny JR, Blazquez J, Moreno A et al. Safe use of pegylated interferon/ ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization. Eur J Gastroenterol Hepatol 2005; 17: 1157-64.
12. Strader DB, Wright T, Thomas DL, Seeff LB. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
13. McHutchison JG, Manns M, Patel K et al., International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
14. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-hispanic whites. N Engl J Med 2004; 350: 2265-71.
15. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355: 2444-51.
16. Horoldt B, Haydon G, O'Donnell K, Dudley T, Nightingale P, Mutimer D. Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection. Liver Int 2006; 26: 650-9.
17. Akuta N, Suzuki F, Kawamura Y et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol 2007; 79: 1686-95.
18. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002; 36: S74-83.
19. Iwasaki Y, Ikeda H, Araki Y et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 2006; 43: 54-63.
20. Yu ML, Dai CY, Huang JF et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553-9.
21. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36: S237-44.
22. Hayashi PH, Mehia C, Joachim Reimers H, Solomon HS, Bacon BR. Splenectomy for thrombocytopenia in patients with hepatitis C cirrhosis. J Clin Gastroenterol 2006; 40: 740-4.
23. Watanabe Y, Horiuchi A, Yoshida M et al. Significance of laparoscopic splenectomy in patients with hypersplenism. World J Surg 2007; 31: 549-55.
24. Vujic I, Lauver JW. Severe complications from partial splenic embolization in patients with liver failure. Br J Radiol 1981; 54: 492-5.
25. Sakai T, Shiraki K, Inoue H et al. Complications of partial splenic embolization in cirrhotic patients. Dig Dis Sci 2002; 47: 388-91.